Tomer M Mark
Overview
Explore the profile of Tomer M Mark including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1144
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ohlstrom D, Walker Z, Pandey A, Davis L, Engel K, Pan Z, et al.
Cancer Res Commun
. 2024 Dec;
5(1):106-118.
PMID: 39699274
scRNA-seq was used to study a patient with high-risk multiple myeloma featuring LCE. LCE was rooted in a transcriptomic subpopulation that corresponded to a genetic subclone and established novel links...
2.
VanWyngarden M, Walker Z, Su Y, Perez de Acha O, Stevens B, Forsberg P, et al.
Cancers (Basel)
. 2023 Nov;
15(22).
PMID: 38001595
An antibody-drug conjugate (ADC) targeting CD46 conjugated to monomethyl auristatin has a potent anti-myeloma effect in cell lines in vitro and in vivo, and patient samples treated ex vivo. Here,...
3.
Binder A, Walker C, Mark T, Baljevic M
Front Immunol
. 2023 Nov;
14:1275329.
PMID: 37954586
Competent T-cells with sufficient levels of fitness combat cancer formation and progression. In multiple myeloma (MM), T-cell exhaustion is caused by several factors including tumor burden, constant immune activation due...
4.
Perez de Acha O, Reiman L, Jayabalan D, Walker Z, Bosma G, Keller A, et al.
Blood Adv
. 2023 Aug;
7(21):6430-6440.
PMID: 37648670
Monoclonal antibodies targeting CD38 are important for treatment of both newly diagnosed and relapsed multiple myeloma (MM). Daratumumab and isatuximab are anti-CD38 antibodies with the US Food and Drugs Administration...
5.
Sonneveld P, Chanan-Khan A, Weisel K, Nooka A, Masszi T, Beksac M, et al.
J Clin Oncol
. 2022 Nov;
41(8):1600-1609.
PMID: 36413710
Purpose: At the primary analysis of CASTOR (median follow-up, 7.4 months), daratumumab plus bortezomib and dexamethasone (D-Vd) significantly prolonged progression-free survival versus bortezomib and dexamethasone (Vd) alone in relapsed or...
6.
Lakritz S, Forsberg P, Sherbenou D, Mark T
Clin Case Rep
. 2022 Oct;
10(9):e6199.
PMID: 36188028
Lenalidomide is an IMiD drug which has been associated with a variety of potential immune related complications. We describe the case of a patient with newly diagnosed multiple myeloma along...
7.
Stalker M, Mark T
Curr Oncol
. 2022 Jul;
29(7):4464-4477.
PMID: 35877215
Major progress has been made in the upfront treatment of multiple myeloma, but the disease ultimately relapses and leads to death in the vast majority of those afflicted. New treatment...
8.
Keller A, Sherbenou D, Forsberg P, Mark T
Front Oncol
. 2022 Jul;
12:925818.
PMID: 35814431
Multiple myeloma is an incurable hematologic malignancy. The typical disease course for myeloma patients is characterized by initial response to treatment followed by eventual development of resistance. Subsequent cycles of...
9.
Forsberg P, Rossi A, Boyer A, Pearse R, Pekle K, Jayabalan D, et al.
Am J Hematol
. 2021 Aug;
96(12):1554-1562.
PMID: 34424561
Combination treatment regimens including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD) and a corticosteroid are standards of care for initial treatment of multiple myeloma (MM). We aimed to evaluate...
10.
Hungria V, Beksac M, Weisel K, Nooka A, Masszi T, Spicka I, et al.
Br J Haematol
. 2021 Feb;
193(3):561-569.
PMID: 33555030
In the phase III CASTOR trial, daratumumab, bortezomib and dexamethasone (D-Vd) significantly extended progression-free survival compared with bortezomib and dexamethasone (Vd) alone in patients with relapsed/refractory multiple myeloma (RRMM). Here,...